A new publicly available tumor organoid biobank has mapped clinically annotated cancer cell dependencies across 256 organoids, using whole-genome/transcriptome sequencing and genome-wide CRISPR–Cas9 screens, according to the study text describing the Maos Cancer Cell Dependencies resource. The work spans colorectal, oesophageal, ovarian, pancreatic, and gastric cancers and aims to bridge gaps between cell lines and patient-matched tumor biology. The authors report systematic mapping of gene dependencies, including organoid-specific essential genes, and integrated analysis of genomic and clinical markers tied to sensitivity. The dataset includes perturbation evidence across 162 organoids and provides targetable vulnerabilities following tumor evolution in paired pre- and post-treatment samples. In colorectal cancer, functional interrogation of the EGFR–RAS–MAPK axis suggests differential effects depending on KRAS variant alleles, supporting a more genotype-informed view of pathway targeting. The publication positions the biobank as renewable and more genetically stable than standard cell line collections. For precision oncology teams, this type of dependency atlas can accelerate target prioritization and help interpret which pathway alterations translate into actionable vulnerabilities within patient-derived contexts.